Cocrystal Pharma Inc (COCP)

Cocrystal Pharma (COCP) Income Statement


Cocrystal Pharma Income Statement

Last quarter (Q3 2023), Cocrystal Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Cocrystal Pharma's net income was $-7.37M. See Cocrystal Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 2.01M$ 6.56M$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ -831.00K$ -18.14M$ 14.22M$ 11.60M$ 8.87M$ 9.02M
Operating Income
$ -8.17M$ -18.14M$ -14.22M$ -9.59M$ -2.30M$ -9.02M
Net Non Operating Interest Income Expense
$ 460.00K$ -2.00K$ -4.00K$ -8.00K$ -19.00K$ -58.00K
Other Income Expense
$ 12.00K$ 20.70M$ -49.00K$ -54.00K$ -45.85M$ -53.55M
Pretax Income
$ -11.00M$ -38.84M$ -14.19M$ -9.65M$ -48.17M$ -62.63M
Tax Provision
---$ 0.00$ 0.00$ -13.58M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -11.00M$ -38.84M$ -14.19M$ -9.65M$ -48.17M$ -49.05M
Basic EPS
$ -5.24$ -4.77-$ -0.17$ -1.51$ -1.75
Diluted EPS
$ -1.46$ -4.77$ -1.92$ -0.17$ -1.51$ -1.75
Basic Average Shares
$ 36.50M$ 8.14M$ 7.36M$ 55.22M$ 31.86M$ 28.01M
Diluted Average Shares
$ 28.36M$ 8.14M$ 7.36M$ 55.22M$ 31.86M$ 28.01M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -831.00K$ 38.83M$ 14.22M$ 11.60M$ 8.87M$ 9.02M
Net Income From Continuing And Discontinued Operation
$ -18.02M$ -38.84M$ -14.19M$ -9.65M$ -48.17M$ -49.05M
Normalized Income
$ -7.51M$ -9.06M-$ -9.59M$ -2.32M$ -7.12M
Interest Expense
---$ 8.00K$ 19.00K$ 58.00K
$ -11.46M$ -35.63M$ -14.18M$ -9.64M$ -48.15M$ -62.57M
$ -11.29M$ -35.45M$ -13.99M$ -9.48M$ -47.90M$ -62.52M
Currency in USD

Cocrystal Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis